Kednapa Thavorn profile picture

Contact Information

Kednapa Thavorn, BPharm, MPharm, PhD
(613)-7378899 ext 72330

Research Administrative Assistant:
Jennifer Brownrigg
Telephone: 613-737-8899
Extension: 73810

ORCID logo


Selected Publications

Papers in refereed journals: (N=221)

  1. Singh S, Tahsin F, Nie JX, McKinstry B, Thavorn K, Upshur R, Harvey S, Wodchis W, Gray CS. Exploring the perspectives of primary care providers on use of the electronic Patient Reported Outcomes tool to support goal-oriented care: A qualitative study. BMC Medical Informatics and Decision Making. 2021;21, 366.

  2. Nochaiwong S, Ruengorn C, Awiphan R, Chai-Adisaksopha C, Sood MM, Hutton B, Thavorn K. Use of Serotonin Reuptake Inhibitor Antidepressants Concomitant with Antithrombotic Therapy and the Risk of Bleeding Complications: A Systematic Review and Meta-Analysis. Annals of Medicine. 2021;54(1):80-97

  3. Nochaiwong S, Chuamanochan M, Ruengorn C, Awiphan R, Tovanabutra N, Chiewchanvit S, Hutton B, Thavorn K. Impact of Pharmacological Treatments for Chronic Spontaneous Urticaria with an Inadequate Response to H1-antihistamines on Health-Related Quality of Life: A Systematic Review and Network Meta-Analysis. The Journal of Allergy and Clinical Immunology: In Practice. 2021; 22:S2213-2198(21)01141-7.

  4. Thavorn K, Kumar S*, Reis C, Lam J, Dobell G, Mulhall C, Grimshaw J, Ivers N. Audit Feedback Interventions to Address High-Risk Prescriptions in Long-Term Care Homes: A Costing Study and Return on Investment Analysis. Implementation Sciences and Complications. 2021; 28;2(1):125.

  5. Kumar S*, Shen J, Grimes D, Mestre T, Thavorn K. Return on Investment Analysis for the Integrated Parkinson’s Care Network: Lesson Learned from a Pilot Study. Journal of Parkinson's Disease. 2021. doi: 10.3233/JPD-212578.

All Other Publications

  1. Kimpton M*, Kumar S*, Wells PS, Coyle D, Carrier M, Thavorn K. Cost-utility analysis of apixaban compared to usual care for the primary thromboprophylaxis of cancer patients. CMAJ. 2021; 193 (40) E1551-E1560; DOI:

  2. Tu MM*, Clemons M, Stober C, Jeong A, Vandermeer L, Mates M, Blanchette P, Joy AA, Aseyev O, Pond G, Fergusson F, Ng T, Thavorn K. Cost-effectiveness analysis of 12- versus 4-weekly administration of bone-targeted agents in patients with bone metastases from breast and castration-resistant prostate cancer. Current Oncology. 2021: 13;28(3):1847-1856. doi: 10.3390/curroncol28030171.

  3. Kumar S, Thavorn K, van Katwyk S, Lasso A, Kilty S. Economic Evaluation of Endoscopic Polypectomy in Clinic Compared to Endoscopic Sinus Surgery: A Modelling Study. Clin Otolaryngol. 2020;45(4):477-485.

  4. van Katwyk S, Augustine S, Thébaud B, Thavorn K. Lifetime patient outcomes and healthcare utilization for Bronchopulmonary dysplasia (BPD) and extreme preterm infants: a microsimulation study. BMC Pediatrics. 2020;20(1):136. doi: 10.1186/s12887-020-02037-5.

  5. van Katwyk S, Ferretti E, Kumar S, Hutton B, Harrold J, Walker M, Forster AJ, Thavorn K. Economic Analysis of Exclusive Human Milk Diets for High-Risk Neonates, a Canadian Hospital Perspective. Breastfeeding Medicine.2020;15(6):377-386. doi:10.1089/bfm.2019.0273.

  6. Isenberg SR, Tanuseputro P., Spruin S., Seow H., Goldman R, Thavorn K, Hsu AT. Cost-effectiveness of investment in end-of-life home care to enable death in community settings. Medical Care. 2020;58(8):665-673. doi:10.1097/MLR.0000000000001320

  7. Nithianandan H, Thavorn K, Banaz F, Macdonald K, Lasso A, Kilty S. Determining the hospital cost of anterior epistaxis treatment modalities at a Canadian tertiary care centre. World Journal of Otorhinolaryngology - Head and Neck Surgery. 2019.

  8. Rockley M, Kobewka D, Kunkel E, Nagpal S, McIsaac D, Thavorn K, Forster A. Characteristics of High-cost Inpatients with Peripheral Arterial Disease. Journal of Vascular Surgery. 2020: pii: S0741-5214(19)32570-4.

  9. Stewart D, Blair MD, Awan A, Thavorn K. Optimal frequency of scans for patients on cancer therapies: A population kinetics assessment. Cancer Medicine. 2019. 8(16):6871-6886. doi: 10.1002/cam4.2571.

  10. Arroxelass M, Clemons M, Van Katwyk S, Carol S, Robertson S, Vandermeer L, Fergusson D, Thavorn K. Cost analysis of using Magee scores as a surrogate of Oncotype Dx® for adjuvant treatment decisions in women with early breast cancer. Journal of Evaluation in Clinical Practice. 2019. 2019;1-4.

  11. Black CD, Thavorn K, Coyle D, Bjerre L. The health system costs of potentially inappropriate prescribing: a population-based, retrospective cohort study using linked health administrative databases in Ontario, Canada. Pharmacoeconomic Open. 2019. doi: 10.1007/s41669-019-0143-2.

  12. Petrosyan Y, Thavorn K, Maclure M, Smith G, McIsaac D, Schramm D, Moloo H, Preston R, Forster AJ. Long-term health outcomes and health system costs associated with surgical site infections: a retrospective cohort study. Annals of Surgery. 2021;273(5):917-923. doi: 10.1097/SLA.0000000000003285.

  13. van Katwyk S, Thavorn K, Coyle D, Moloo H, Forster AJ, Jackson T, Schramm D. The return of investment of hospital-based surgical quality improvement programs in reducing surgical site infection at a Canadian tertiary-care hospital. Infection Control & Hospital Epidemiology. 2018:1-8.

  14. Robin P, Kumar S, Saluan PY, Le Roux PY, Couturaud F, Planquette B, Merah A, Roy PM, Thavorn K, Le Gal G. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems. Thrombosis Research. 2018; 171:97-102.

  15. Le A, Thavorn K, Lasso A, Kilty SJ. Economic Evaluation of Floseal Compared to Nasal Packing for the Management of Anterior Epistaxis. The Laryngoscope. 2018 Jan 4.

  16. Nochaiwong S, Ruengorn C, Awiphan R, Koyratkoson K, Chaisai C, Noppakun K, Thavorn K. The association between proton pump inhibitors use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrology Dialysis Transplantation. 2018; 33(2):331-342.

  17. Huang A, Thavorn K, Van Katwyk S, MacDonald P, Lapner P. Double-Row Arthroscopic Rotator Cuff Repair Is More Cost-Effective Than Single-Row Repair. The Journal of Bone & Joint Surgery. 2017. 99(20):1730-1736.

  18. Tricco A, Cogo E, Thomas S, Hamid J, Strifler L, Khan P, Sibley K, Robson R, MacDonald H, Riva J, Thavorn K, Wilson C, Holroyd-Leduc J, Kerr G, Feldman F, Majumdar S, Jaglal S, Hui W, Straus S. Comparative Efficacy of Preventing Falls in Older Adults: A systematic review and network meta-analysis. JAMA. 2017. 318(17):1687-1699.

  19. Thavorn K, Maxwell C, Grunier A, Bronskil S, Kone A, Petrosyan Y, Qing Y, Wodchis W. The Effect of Socio-demographic Factors on the Association between Multimorbidity and Healthcare Costs: A Population-based Study. BMJ Open. 2017;7(10): e017264.

  20. van Katwyk S, Jin YP, Trope GE, Buys Y, Masucci L, Wedge R, Flanagan J, Brent M, El-Defrawy, Tu HA, Thavorn K. Cost-utility analysis of extending public health insurance coverage to include diabetic retinopathy screening by optometrists. Value in Health. 2017 ;20(8):1034-1040.

  21. Van Katwyk S, Coyle D, Cooper C, Pussegoda K, Cameron C, Skidmore B, Brener S, Thavorn K. Transient Elastography in Diagnosing Liver Fibrosis in Patients: A Systematic Review of Economic Evaluations. Liver International. 2017. 37(6):851-861.

  22. Thavorn K, Coyle D, Hoch J, Vandermeer L, Mazzarello S, Wang Z, Dranitsaris G, Fergusson D, Clemons M. A cost-utility analysis of Risk Model-Guided versus Physician's Choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net-benefit regression approach. Supportive Care in Cancer. 2017 Mar 9.

  23. Chen I, Thavorn K, Shen M, Goddard Y, Yong P, MacRae GS, Nishi C, Matar A, Allaire C. Hospital-associated costs of chronic pelvic pain in Canada: a population-based descriptive study. Journal of Obstetrics and Gynaecology Canada. 2017 Mar;39(3):174-180.

  24. Yong JH, Thavorn K, Hoch JS, Mamdani M, Thorpe KE, Dorian P, Sharma M, Laupacis A, Gladstone DJ, EMBRACE Steering Committee. Potential Cost-Effectiveness of Ambulatory Cardiac Rhythm Monitoring After Cryptogenic Stroke. Stroke. 2016; 47(9): 2380-5.

PubMed Listings

For more publications use this PubMed ID link.